SCHEMBL6058482

SCHEMBL6058482

O=C(O)c1c(Cl)sc(Cl)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 5/20 0.42
DPP4 P27487 1/20 0.39
CYP1A2 P05177 1/20 0.35
ALDH1A1 P00352 3/20 0.34
TSHR P16473 2/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GSK3B P49841 1/20 0.32
ALOX15 P16050 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
TPMT P51580 1/20 0.32
GPR35 Q9HC97 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18701547 0.86 GSK3B (0.42) DAODPP4CYP1A2ALDH1A1TSHR
SCHEMBL18701677 0.84 ALDH1A1 (0.39) DAODPP4ALDH1A1TSHRHPGD
SCHEMBL19733065 0.82 DAO (0.39) DAODPP4CYP1A2ALDH1A1TSHR
SCHEMBL8629628 0.82 DAO (0.42) DAODPP4ALDH1A1TSHRHPGD
SCHEMBL18701838 0.82 DAO (0.35) DAODPP4
SCHEMBL18701671 0.82 DAO (0.35) DAODPP4
SCHEMBL19746574 0.82 DAO (0.38) DAOALDH1A1TSHRHPGDKDM4E
SCHEMBL18701608 0.76 MCL1 (0.42) DAODPP4ALDH1A1TSHRHPGD
SCHEMBL17043011 0.75 DAO (0.35) DAOCYP1A2ALDH1A1TSHRMAPK1
SCHEMBL18701546 0.75 DAO (0.34) DAODPP4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119465642-A Conductive filament applied to intelligent wearable equipment and preparation method thereof 武汉纺织大学 2025-02-18 CN claimed
CN-119465642-A Conductive filament applied to intelligent wearable equipment and preparation method thereof 武汉纺织大学 2025-02-18 CN disclosed
EP-3757107-B1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2023-10-25 EP disclosed
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-10-05 US disclosed
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-10-05 US disclosed
US-20210284652-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2021-09-16 US disclosed
EP-3757107-A1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2020-12-30 EP disclosed
US-10870658-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-12-22 US disclosed
US-20200283451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-09-10 US disclosed
EP-3352754-B1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2020-09-02 EP disclosed
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-12 US disclosed
US-20200131203-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF APPLIED THERAPEUTICS INC (US) 2020-04-30 US disclosed
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-10-03 US disclosed
US-20180282605-A1 METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2018-10-04 US disclosed
WO-2017060699-A1 METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2017-04-13 WO disclosed
EP-1678218-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS Basell Poliolefine Italia S.r.l. (IT) 2006-07-12 EP disclosed
WO-2005047351-A1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE ITALIA S.R.L. (IT) 2005-05-26 WO disclosed
US-4028373-A ARTIFICIAL SWEETNERS BASF AKTIENGESELLSCHAFT (DT) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870658-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885
US-20200131203-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 DAO 642/4885DPP4 1148/4885CYP1A2 280/4885
US-20200283451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885
US-20210284652-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885DPP4 704/4885CYP1A2 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.